Rhenman & Partners Asset Management AB
Stockholm, V7
$1.1bn in 99 US stocks at the end of 30 June 2026. The top 10 are 25.1% of the money. It changed about 28.9% of the portfolio this quarter.
Value
$1.1bn
Stocks
99
Top 10 share
25.1%
Turnover
28.9%
What changed this quarter
New
Bought for the first time this quarter.
- AstrazenecaAZN2.7% of the fund
- MerckMRK2.6% of the fund
- Johnson & JohnsonJNJ1.7% of the fund
- CenteneCNC1.5% of the fund
- DexcomDXCM1.0% of the fund
- Spyre TherapeuticsSYRE1.0% of the fund
- Oruka TherapeuticsORKA0.7% of the fund
- ErascaERAS0.6% of the fund
- Astrana HealthASTH0.5% of the fund
- Molina HealthcareMOH0.5% of the fund
- AMN Healthcare ServicesAMN0.4% of the fund
- Medpace HoldingsMEDP0.4% of the fund
- Ascendis Pharma A/SASND0.4% of the fund
- MBX BiosciencesMBX0.3% of the fund
- Bicara TherapeuticsBCAX0.2% of the fund
- Privia Health GroupPRVA0.1% of the fund
- MiniMed GroupMMED<0.1% of the fund
- agilon healthAGL<0.1% of the fund
- 10x GenomicsTXG<0.1% of the fund
- Tandem Diabetes CareTNDM<0.1% of the fund
- TG TherapeuticsTGTX<0.1% of the fund
Added
Bought more of a stock they already held.
- UnitedHealth GroupUNH3.7% of the fund+106%
- AbbVieABBV2.3% of the fund+35%
- Edwards LifesciencesEW2.2% of the fund+60%
- Gilead SciencesGILD2.1% of the fund+6%
- Jazz PharmaceuticalsJAZZ2.0% of the fund+15%
- StrykerSYK1.9% of the fund+36%
- GlaukosGKOS1.6% of the fund+42%
- Biomarin PharmaceuticalBMRN1.6% of the fund+40%
- Nurix TherapeuticsNRIX1.6% of the fund+118%
- NateraNTRA1.6% of the fund+18%
- Mirum PharmaceuticalsMIRM1.5% of the fund+50%
- Tenet HealthcareTHC1.5% of the fund+58%
- DanaherDHR1.4% of the fund+345%
- Anteris Technologies GlobalAVR1.4% of the fund+7%
- Pennant GroupPNTG1.3% of the fund+35%
- Elevance HealthELV1.3% of the fund+8%
- LivaNovaLIVN1.3% of the fund+6%
- Charles River Laboratories InternationalCRL1.2% of the fund+120%
- IDEAYA BiosciencesIDYA1.2% of the fund+35%
- Syndax PharmaceuticalsSNDX1.2% of the fund+48%
- BrightSpring Health ServicesBTSG1.1% of the fund+232%
- MedtronicMDT1.1% of the fund+61%
- Mineralys TherapeuticsMLYS1.1% of the fund+58%
- Align TechnologyALGN1.0% of the fund+740%
- Relay TherapeuticsRLAY1.0% of the fund+57%
Cut
Sold some of their stake.
- CVS HealthCVS2.7% of the fund-17%
- Eli LillyLLY2.5% of the fund-34%
- Alignment HealthcareALHC2.2% of the fund-5%
- BiogenBIIB1.9% of the fund-13%
- Boston ScientificBSX1.8% of the fund-28%
- Guardant HealthGH1.6% of the fund-21%
- Regeneron PharmaceuticalsREGN1.6% of the fund-43%
- InsmedINSM1.5% of the fund-5%
- Thermo Fisher ScientificTMO1.5% of the fund-24%
- Vertex PharmaceuticalsVRTX1.4% of the fund-29%
- Neurocrine BiosciencesNBIX1.4% of the fund-15%
- Intuitive SurgicalISRG1.3% of the fund-6%
- CencoraCOR1.2% of the fund-11%
- Oscar HealthOSCR1.1% of the fund-41%
- Royalty PharmaRPRX1.0% of the fund-15%
- Arrowhead PharmaceuticalsARWR1.0% of the fund-11%
- Abbott LaboratoriesABT0.8% of the fund-14%
- PROCEPT BioRoboticsPRCT0.7% of the fund-27%
- Iovance BiotherapeuticsIOVA0.7% of the fund-17%
- Krystal BiotechKRYS0.6% of the fund-2%
- Cardinal HealthCAH0.5% of the fund-17%
- Alnylam PharmaceuticalsALNY0.5% of the fund-50%
- Viking TherapeuticsVKTX0.5% of the fund-20%
- Ionis PharmaceuticalsIONS0.4% of the fund-36%
- Denali TherapeuticsDNLI0.4% of the fund-10%
Sold out
Sold their entire stake.
- Adaptive BiotechnologiesADPT-100%
- Iqvia HoldingsIQV-100%
- Nuvalent-100%
- Apogee TherapeuticsAPGE-100%
- Ascendis Pharma A/SASND-100%
- Esperion Therapeutics INC NE-100%
- Immunocore HldgsIMCR-100%
- Compass TherapeuticsCMPX-100%
Holdings
- Structure TherapeuticsGPCR
- Share
- 0.7%
- Value
- $8m
- Shares
- 145,100
+13%
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 33.9% since 30 June 2025.
Where the money is
Health care94.7%
Financial services3.3%
Technology0.8%
Industrials0.5%
Other0.7%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.